Supernus Pharmaceuticals
Supernus Pharmaceuticals Inc is an American biopharmaceutical company focused on central nervous system therapies for neurological and psychiatric disorders. The company develops and commercializes prescription medicines including Qelbree for ADHD, Oxtellar XR and Trokendi XR for epilepsy, and Gocovri and APOKYN for Parkinson's disease. Main revenue drivers consist of commercial drug sales of proprietary CNS prescription pharmaceuticals through pharmaceutical wholesalers and specialty pharmacies. Supernus Pharmaceuticals serves psychiatrists, neurologists, movement disorder specialists, and patients across the United States. The company holds an established market position in central nervous system therapeutics and Parkinson's disease management. Headquartered in Rockville, Maryland, Supernus Pharmaceuticals Inc is listed on the Nasdaq Stock Market.
4 of the funds FundTelligence covers report a position in Supernus Pharmaceuticals.
- Legal name
- Supernus Pharmaceuticals Inc
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 4
- Exposure themes
- ADHD, Mental Health, Neuropsychiatry
Funds holding Supernus Pharmaceuticals
- Aberdeen North American Smaller Companies Fund — Abrdn · 2.4 % (largest positions only, September 2026)
- Handelsbanken Global SMB Index Criteria — Handelsbanken · 0.03 % (full portfolio disclosed, October 2026)
- KLP AksjeGlobal Small Cap Indeks — KLP · 0.02 % (partially disclosed portfolio, June 2026)
- DNB Global Enhanced Small Cap — DNB · 0.0 % (full portfolio disclosed, September 2026)